Christoph Adams

FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA.

Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.

Cydan II, Inc. develops and commercializes drugs for orphan and diseases. The firm evaluates products for treating rare diseases with high unmet medical need to start multiple companies to develop such therapies. The company was founded by Cristina Csimma, James G. McArthur, Deborah S. Geraghty and Christoph M. Adams in 2013 and is headquartered in Cambridge, MA.

Vtesse, Inc. provides novel drugs for life-threatening rare diseases. It developed VTS-270, a modified form of cyclodextrin that has been evaluated in preclinical and clinical studies at institutes within the National Institutes of Health (NIH) to treat patients with Niemann-Pick Disease Type C (NPC). The firm is working with the NIH and other leading academic centers to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs. The company was founded by Ben Machielse in 2015 and is headquartered in Gaithersburg, MD.

Imara, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel therapeutics to treat patients suffering from hemoglobinopathies. The company was founded by James Gregg McArthur in 2016 and is headquartered in Brookline, MA.

Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA.

Aviceda Therapeutics, Inc. is a biotech company which specializes in clinical sciences, clinical research, and drug development. The firm focuses on glyco-immune therapeutics utilizing the Glyco-Code technology platform to address the innate immune system and chronic non-resolving inflammation. The company was founded by Mohamed Genead, Michael Tolentino, Derek Kunimoto, and Christopher Scott and is headquartered in Cambridge, MA.